Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes    » A1c    » Adolescents    » Awareness    » Cause    » Children    » Complications    » Control    » Costs    » Cure    » Diagnosis    » Drugs    » Elderly    » Gestational    » Hypoglycemia    » Impaired Fasting Glucose    » Impaired Glucose Tolerance    » Inflammation    » Insulin Resistance    » Insulin Sensitivity    » Men    » Metabolic Syndrome    » Minorities    » Obesity    » Organs    » Other Diseases    » Pancreas    » Pre-Diabetes    » Prevention    » Research    » Risk Factors    » Screening    » Statistics    » Stress    » Syndrome X    » Testing    » Treatments    » Type 1    » Type 2    » Warning Signs    » Women Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

About Diabetes » Control

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Why Diabetics Over-Produce Sugar in the Liver Posted: Sunday, May 24, 2009

Type 2 diabetics often suffer from an over-production of sugar within the liver, a response to falling blood glucose levels. This potentially dangerous mechanism was poorly understood until recently, when researchers uncovered the role that a certain "master regulator" plays in sugar production within the liver.

The Economics of Undiagnosed Diabetes Posted: Wednesday, May 20, 2009

Approximately 6.3 million adults - or one-fourth of the people in the U.S. with diabetes mellitus - are unaware they have the disease, and this undiagnosed population accounts for an estimated $18 billion in health care costs each year.

Low Blood Sugar and Kidney Disease: A Killer Posted: Wednesday, May 20, 2009

Low blood sugar, or hypoglycemia, poses a serious health threat for patients with chronic kidney disease (CKD), according to a new study. The findings indicate that hypoglycemia may account for some portion of the excess heart-related deaths seen in CKD patients.

Pharmacists Prove their Worth in Diabetes Management Posted: Wednesday, May 20, 2009

Pharmacists show why they need to be part of the “Diabetes Team” and the Ten City Challenge diabetes education program shows that they can also reduce costs ($1,079/patient) as well as reducing A1c levels along with cholesterol and blood pressure.

New Guidelines Address Treatment of Hospitalized Patients with High Blood Sugars Posted: Wednesday, May 20, 2009

A consensus statement of the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) issues clinical recommendations on the proper treatment of hospitalized patients with high blood glucose levels.

Children Eating Themselves into an Early Grave Posted: Wednesday, May 20, 2009

Children are eating themselves into an early grave with hundreds of thousands of primary school pupils already suffering from chronic disease, a study has found.

Intensive Medical Intervention Successful in Primary Care Setting for Obese Patients Posted: Wednesday, May 20, 2009

Patients with extreme obesity achieved 8.3% weight loss after 2 years of intensive medical intervention compared with 0.5% in a control group, according to new research.

Lyrica Significantly Reduced Peripheral Nerve Pain Posted: Wednesday, May 20, 2009

Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, according to new data.

CHMP Recommends Approval of Novo Nordisk's Victoza(R) (Liraglutide) for Type 2 Diabetes Posted: Wednesday, May 20, 2009

Novo Nordisk announces that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMEA) adopted a positive opinion, recommending marketing authorization, for Victoza® for the treatment of Type 2 diabetes.

Basal-Bolus Injection vs. Basal-Bolus Insulin Pump in Type 1s Posted: Wednesday, May 20, 2009

To compare injects by syringe and using an insulin pump a randomized open parallel multicenter study was done.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.